< Back to companies
GV20 Oncotherapy (寻百会)

GV20 Oncotherapy (寻百会)

Shanghai, China

GV20 Oncotherapy (寻百会) was started by expert team from Harvard University. We are devoted in cancer immuno-oncology precision medicine development. GV20 Oncotherapy has created new generation of cancer novel drug discovery and development platform which integrates cancer genomics, antibody drug design and biological big data mining. We are utilizing our technological advantages to search novel immuno-oncology targets, screen tumor-specific fully human antibody and identify robust response biomarkers.

Share
Shareable draft
Get Involved in GV20 Oncotherapy (寻百会)

Company Info

Founded
2016
Website
www.bioxbh.com/

Categories

CancerPrecision Medicine/Diagnostics

Disease Areas

Technologies

ImmunotherapyPrecision Medicine TechDrug Development
Only accessible to MedStartr community members. Join now

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Sign in to join the conversation.

Sign in to comment
Be the first to comment.

What do you think of GV20 Oncotherapy (寻百会)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Your scores and comments are shown with your review on this company's profile.

Get Involved in GV20 Oncotherapy (寻百会)
💬

Hi, I'm Syggy!

MedStartr's AI healthcare innovation superhero. Just click me for whatever you need! 🥰

💬
Hi, I'm Syggy
your healthcare innovation buddy
💬

Ask Syggy anything

What MedStartr is, how it can help you, events, joining...

You're chatting as a visitor: this conversation stays in this browser, isn't linked to any account, and doesn't move over if you join. Join free